Atomo Diagnostics Ltd.

As of June 30, 2026, Atomo Diagnostics Ltd. carries a market capitalization of 15.34M, placing it among publicly traded companies globally. Its enterprise value stands at 12.01M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Atomo Diagnostics Ltd.'s next confirmed earnings release is scheduled for February 24, 2027.

As of June 30, 2026, Atomo Diagnostics Ltd. has 902.43M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.69, and the price-to-book ratio stands at 1.99.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.30 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 12.01M versus a market cap of 15.34M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Atomo Diagnostics Ltd. maintains a current ratio of 3.04, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Atomo Diagnostics Ltd. posted a negative return on equity (ROE) of -47.86, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -34.96, reflecting losses generated across the asset base. Inventory turnover of 1.91 indicates how many times Atomo Diagnostics Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Atomo Diagnostics Ltd.'s stock has declined approximately 37.04% over the past 52 weeks. The 50-day moving average sits at 0.02, while the 200-day moving average is 0.03.

Over the twelve months ended June 30, 2026, Atomo Diagnostics Ltd. generated 5.23M in revenue and converted that into -3.51M in net income, yielding earnings per share of 0.00. EBITDA reached -4.37M, while operating income came in at -5.79M.

As of June 30, 2026, Atomo Diagnostics Ltd. holds 3.71M in cash and equivalents against 373,082.00 in total debt, resulting in a net debt position of -3.71M. Total book value stands at 7.71M, with working capital of 5.97M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Atomo Diagnostics Ltd. posted a gross margin of 33.92, reflecting its pricing power and cost economics. The operating margin of -110.84 and net profit margin of -67.21 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -24.87, meaning Atomo Diagnostics Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Atomo Diagnostics Ltd. has an Altman Z-Score of -7.73, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.